Financial Ratios

SUPRIYA PHARMACEUTICALS LTD.

NSE : NABSE : 524784ISIN CODE : INE647C01016Industry : Pharmaceuticals & DrugsHouse : Private
BSE10.300 (0 %)
PREV CLOSE ( ) 10.30
OPEN PRICE ( ) 10.30
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 0
TODAY'S LOW / HIGH ( )10.30 10.30
52 WK LOW / HIGH ( ) 00
NSE
This Company is not listed in NSE
Select year
ParticularsSep2004Sep2003Sep2002Sep1999Jun1998
Operational & Financial Ratios
   Earnings Per Share (Rs)-0.721.804.412.50-5.36
   CEPS(Rs)0.012.515.093.57-4.48
   DPS(Rs)0.000.000.000.000.00
   Book NAV/Share(Rs)8.529.036.73-0.85-3.48
   Tax Rate(%)0.000.000.000.610.00
Margin Ratios
   Core EBITDA Margin(%)-53.5214.0311.611.52-24.77
   EBIT Margin(%)-9.0814.7215.951.70-7.87
   Pre Tax Margin(%)-11.0611.2314.671.48-9.79
   PAT Margin (%)-11.0611.2314.671.47-9.79
   Cash Profit Margin (%)0.1915.7216.942.10-8.19
Performance Ratios
   ROA(%)-3.899.2515.417.16-17.08
   ROE(%)-8.2122.79150.000.000.00
   ROCE(%)-5.5527.36115.81680.04-321.87
   Asset Turnover(x)0.350.821.054.881.74
   Sales/Fixed Asset(x)0.541.362.8017.406.09
   Working Capital/Sales(x)2.028.91-46.05-40.19-8.71
Efficiency Ratios
   Fixed Capital/Sales(x)1.860.740.360.060.16
   Receivable days130.8666.5830.684.5924.89
   Inventory Days313.13161.23188.6145.57102.09
   Payable days478.66420.09147.2116.1043.26
Valuation Parameters
   PER(x)0.000.000.000.000.00
   PCE(x)282.710.000.000.000.00
   Price/Book(x)0.420.000.000.000.00
   Yield(%)0.00
   EV/Net Sales(x)0.980.740.360.070.28
   EV/Core EBITDA(x)43.173.651.843.02-3.74
   EV/EBIT(x)-10.324.772.104.14-2.98
   EV/CE(x)0.340.590.510.320.40
   M Cap / Sales0.570.000.000.000.00
Growth Ratio
   Net Sales Growth(%)-59.31-44.88-83.73265.982.26
   Core EBITDA Growth(%)-95.39-43.9337.91215.8967.08
   EBIT Growth(%)-125.15-50.9165.72167.2060.95
   PAT Growth(%)-140.14-59.2776.65146.6157.34
   EPS Growth(%)-140.14-59.2776.65146.6157.34
Financial Stability Ratios
   Total Debt/Equity(x)0.300.140.03-2.58-0.86
   Current Ratio(x)1.321.150.960.880.80
   Quick Ratio(x)0.910.550.500.200.22
   Interest Cover(x)-4.594.2212.447.57-4.10
   Total Debt/Mcap(x)0.72

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.